Assessment of Comorbidities for Hematopoietic Cell Transplants: Achievements and Controversies

Hillard M. Lazarus: Affiliation:
Case Western Reserve University, Ohio
Robert Peter Gale: Affiliation:
Imperial College London
Armand Keating: Affiliation:
University of Toronto
Andrea Bacigalupo: Affiliation:
Ospedale San Martino, Genoa
Reinhold Munker: Affiliation:
Louisiana State University, Shreveport
Kerry Atkinson: Affiliation:
University of Queensland
Syed Ali Abutalib: Affiliation:
Midwestern Regional Medical Center, Cancer Treatment Centers of America, Chicago

Book contents

Get access

Type: Chapter
Information: Hematopoietic Cell Transplants
Concepts, Controversies and Future Directions
, pp. 23 - 42

DOI: https://doi.org/10.1017/9781316335727.005 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2000

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Thomas, ED, Blume, KG, Forman, SJ, eds. Hematopoietic Cell Transplantation. 2nd edition. Blackwell Science, Inc., Boston, MA: 1999Google Scholar PubMed

Atkinson, K, ed. Clinical Bone Marrow and Blood Stem Cell Transplantation. 2nd edition. Cambridge University Press, Cambridge, UK: 2000Google Scholar

Fried, LP, Bandeen-Roche, K, Kasper, JD, Guralnik, JM. Association of comorbidity with disability in older women: the Women’s Health and Aging Study. J Clin Epidemiol 52(1): 27–37, 1999CrossRef Google Scholar PubMed

van Spronsen, DJ, Janssen-Heijnen, ML, Breed, WP, Coebergh, JW. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin’s disease and non-Hodgkin’s lymphoma, 1993–1996. Ann Hematol 78(7): 315–9, 1999CrossRef Google Scholar PubMed

Greimel, ER, Padilla, GV, Grant, MM. Physical and psychosocial outcomes in cancer patients: a comparison of different age groups. Br J Cancer 76(2): 251–5, 1997CrossRef Google Scholar PubMed

Kurtz, ME, Kurtz, JC, Stommel, M, Given, CW, Given, B. The influence of symptoms, age, comorbidity and cancer site on physical functioning and mental health of geriatric women patients. Women Health 29(3): 1–12, 1999CrossRef Google Scholar PubMed

Given, CW, Given, B, Azzouz, F, Stommel, M, Kozachik, S. Comparison of changes in physical functioning of elderly patients with new diagnoses of cancer. Med Care 38(5): 482–93, 2000CrossRef Google Scholar PubMed

Pinto, A, Zagonel, V, Ferrara, F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies (Review). Crit Rev Oncol Hematol 39(3): 275–87, 2001CrossRef Google Scholar

van Spronsen, DJ, Janssen-Heijnen, ML, Lemmens, VE, Peters, WG, Coebergh, JW. Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry. Eur J Cancer 41(7): 1051–7, 2005CrossRef Google Scholar PubMed

Extermann, M, Overcash, J, Lyman, GH, Parr, J, Balducci, L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16(4): 1582–7, 1998CrossRef Google Scholar PubMed

Charlson, ME, Pompei, P, Ales, KL, MacKenzie, CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5): 373–83, 1987CrossRef Google Scholar PubMed

Sorror, ML, Maris, MB, Storer, B, Sandmaier, BM, Diaconescu, R, Flowers, C, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities. Blood 104(4): 961–8, 2004CrossRef Google Scholar

Sorror, ML, Maris, MB, Storb, R, Baron, F, Sandmaier, BM, Maloney, DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106(8): 2912–9, 2005CrossRef Google Scholar PubMed

Sorror, ML, Sandmaier, BM, Storer, BE, Maris, MB, Baron, F, Maloney, DG, et al. Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 25(27): 4246–54, 2007CrossRef Google Scholar PubMed

Lim, ZY, Ingram, W, Brand, R, Ho, A, Kenyon, M, Devereux, S, et al. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplant 45(4): 633–9, 2010CrossRef Google Scholar PubMed

Mohty, M, Labopin, M, Basara, N, Cornelissen, JJ, Tabrizi, R, Malm, C, et al. Association between the Hematopoietic Cell Transplantation-Specific Comorbidity Index (CI) and non-relapse mortality (NRM) after reduced intensity conditioning (RIC) allogeneic stem cell transplantation (allo-SCT) for acute myeloid leukemia (AML) in first complete remission (CR1). [Abstract] Blood 114(22): 270, #650,2009CrossRef Google Scholar

Kerbauy, DMB, Chyou, F, Gooley, T, Sorror, ML, Scott, B, Pagel, JM, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 11: 713–20, 2005CrossRef Google Scholar PubMed

Sorror, ML, Storer, BE, Maloney, DG, Sandmaier, BM, Martin, PJ, Storb, R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 111(1): 446–52, 2008CrossRef Google Scholar PubMed

Farina, L, Bruno, B, Patriarca, F, Spina, F, Sorasio, R, Morelli, M, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia 23(6): 1131–8, 2009CrossRef Google Scholar PubMed

Pollack, SM, Steinberg, SM, Odom, J, Dean, RM, Fowler, DH, Bishop, MR. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 15(2): 223–30, 2009CrossRef Google Scholar PubMed

Sorror, ML, Storer, BE, Sandmaier, BM, Maris, M, Shizuru, J, Maziarz, R, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol 26(30): 4912–20, 2008CrossRef Google Scholar PubMed

Pavlu, J, Kew, AK, Taylor-Roberts, B, Auner, HW, Marin, D, Olavarria, E, et al. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood 115(20): 4018–20, 2010CrossRef Google Scholar PubMed

Sorror, ML, Giralt, S, Sandmaier, BM, de Lima, M, Shahjahan, M, Maloney, DG, et al. Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences. Blood 110(13): 4608–13, 2007CrossRef Google Scholar PubMed

Appelbaum, FR, Gundacker, H, Head, DR, Slovak, ML, Willman, CL, Godwin, JE, et al. Age and acute myeloid leukemia. Blood 107(9): 3481–5, 2006CrossRef Google Scholar PubMed

Artz, AS, Pollyea, DA, Kocherginsky, M, Stock, W, Rich, E, Odenike, O, et al. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 12(9): 954–64, 2006CrossRef Google Scholar PubMed

Sorror, M, Storer, B, Sandmaier, BM, Maloney, DG, Chauncey, TR, Langston, A, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112: 1992–2001, 2008CrossRef Google Scholar PubMed

Gratwohl, A, Stern, M, Brand, R, Apperley, J, Baldomero, H, de Witte, T, et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 115(20): 4715–26, 2009CrossRef Google Scholar PubMed

Gratwohl, A, Hermans, J, Goldman, JM, Arcese, W, Carreras, E, Devergie, A, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 352(9134): 1087–92, 1998CrossRef Google Scholar PubMed

Elsawy, M, Storer, BE, Sorror, ML. “To combine or not to combine”: Optimizing risk assessment before allogeneic hematopoietic cell transplantation (Letter). Biol Blood Marrow Transplant 20(9):1455–6, 2014CrossRef Google Scholar

Appelbaum, FR. Preparative regimens and ageism. Biol Blood Marrow Transplant 17(10): 1419–20, 2011CrossRef Google Scholar PubMed

Sorror, ML, Storb, R, Sandmaier, BM, Maziarz, RT, Pulsipher, MA, Maris, MB, et al. Comorbidity-age index: a clinical measure of biological age prior to allogeneic hematopoietic cell transplantation. J Clin Oncol 32(29):3249–56, 2014CrossRef Google Scholar

Orszag, PR, Emanuel, EJ. Health care reform and cost control. N Engl J Med 363(7): 601–3, 2010CrossRef Google Scholar PubMed

Kahl, C, Storer, BE, Sandmaier, BM, Mielcarek, M, Maris, MB, Blume, KG, et al. Relapse risk among patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 110(7): 2744–8, 2007CrossRef Google Scholar PubMed

Sorror, ML, Sandmaier, BM, Storer, BE, Franke, GN, Laport, GG, Chauncey, TR, et al. Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 306(17): 1874–83, 2011CrossRef Google Scholar PubMed

Djousse, L, Rothman, KJ, Cupples, LA, Levy, D, Ellison, RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation 106(23): 2919–24, 2002CrossRef Google Scholar PubMed

Deeg, HJ, Spaulding, E, Shulman, HM. Iron overload, hematopoietic cell transplantation, and graft-versus-host disease. Leuk Lymphoma 50(10): 1566–72, 2009Google Scholar PubMed

Sorror, ML, Storer, BE, Schoch, G, Sandmaier, BM, Martin, PJ, Scott, BL, et al. Low albumin, high ferritin, and thrombocytopenia before transplant predict non-relapse mortality (NRM) independent of the hematopoeitic cell transplantation comorbidity index (HCT-CI). [Abstract] Blood 114(22): 271, #651,2009. https://www.ncbi.nlm.nih.gov/pubmed/25862589 CrossRef Google Scholar

Sherman, AE, Motyckova, G, Fega, KR, DeAngelo, DJ, Abel, GA, Steensma, D, et al. Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes. Leuk Res 37(9): 998-1003, 2013CrossRef Google Scholar PubMed

Deschler, B, Ihorst, G, Platzbecker, U, Germing, U, Marz, E, de Figuerido, M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica 98(2): 208–16, 2013CrossRef Google Scholar PubMed

Muffly, LS, Kocherginsky, M, Stock, W, Chu, Q, Bishop, MR, Godley, LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica;99(8):1373–9, 2014CrossRef Google Scholar PubMed

Sorror, ML, Martin, PJ, Storb, R, Bhatia, S, Maziarz, RT, Pulsipher, MA, et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood 124(2): 287–95, 2014CrossRef Google Scholar PubMed

Sorror, ML, Yi, JC, Storer, BE, Rock, EE, Artherholt, SB, Storb, R, et al. Association of pre-transplant comorbidities with long-term quality of life (QOL) among survivors after allogeneic hematopoietic cell transplantation (HCT). [Abstract] Biol Blood Marrow Transplant 19(2): S153, 2013CrossRef Google Scholar

Sorror, ML, Logan, BR, Zhu, X, Rizzo, JD, Cooke, KR, McCarthy, PL, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant 21(8): 1479–87, 2015CrossRef Google Scholar PubMed

Sorror, ML, Ostronoff, F, Storb, R, Bhatia, S, Maziarz, RT, Pulsipher, MA, et al. Multi-institutional validation of the predictive power of the hematopoietic cell transplantation comorbidity index (HCT-CI) for HCT outcomes. [Abstract] Blood 118(21): #145, 2011CrossRef Google Scholar

Smith, AR, Majhail, NS, MacMillan, ML, Defor, TE, Jodele, S, Lehmann, LE, et al. Hematopoietic cell transplantation comorbidity index predicts transplantation outcomes in pediatric patients. Blood 117(9): 2728–34, 2011CrossRef Google Scholar PubMed

Ratan, R, Ceberio, I, Hilden, P, Devlin, SM, Malloy, MA, Barker, JN, et al. The Hematopoietic Cell Transplant-Co-Morbidity Index (HCT-CI) predicts outcomes after T cell depleted (TCD) allogeneic HCT for AML and MDS. [Abstract] Blood 122(21): 2045, 2013CrossRef Google Scholar

Bokhari, SW, Watson, L, Nagra, S, Cook, M, Byrne, JL, Craddock, C, et al. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation. Bone Marrow Transplant 47(4): 528–34, 2012CrossRef Google Scholar PubMed

Le, RQ, Jain, NA, Tian, X, Ito, S, Lu, K, Haggerty, J, et al. Comorbidity measures in ex vivo T cell depleted allogeneic hematopoietic stem cell transplantation (HCT). [Abstract] Blood 122(21), 2013Google Scholar

Sorror, ML. Comorbidities and hematopoietic cell transplantation outcomes. pp. 237–47. In Gewirtz, AM, Mikhael, JR, Schwartz, BS, Crowther, MA, editors. Hematology 2010: American Society of Hematology Education Program Book. American Society of Hematology, Washington, DC: 2010Google Scholar

Kerbauy, DMB, Gooley, TA, Sale, GE, Flowers, MED, Doney, KC, Georges, GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 13(3): 355–65, 2007CrossRef Google Scholar PubMed

Maruyama, D, Fukuda, T, Kato, R, Yamasaki, S, Usui, E, Morita-Hoshi, Y, et al. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. Biol Blood Marrow Transplant 13(8): 932–41, 2007CrossRef Google Scholar PubMed

Artz, AS, Wickrema, A, Dinner, S, Godley, LA, Kocherginsky, M, Odenike, O, et al. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 14(11): 1209–16, 2008CrossRef Google Scholar PubMed

Majhail, NS, Brunstein, CG, McAvoy, S, Defor, TE, Al-Hazzouri, A, Setubal, D, et al. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants. Biol Blood Marrow Transplant 14(9): 985–92, 2008CrossRef Google Scholar

Kataoka, K, Nannya, Y, Ueda, K, Kumano, K, Takahashi, T, Kurokawa, M. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study. Bone Marrow Transplant 45(3): 513–20, 2010CrossRef Google Scholar PubMed

Barba, P, Piñana, JL, Martino, R, Valcárcel, D, Amorós, A, Sureda, A, et al. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. Biol Blood Marrow Transplant 16(3): 413–20, 2010CrossRef Google Scholar

Raimondi, R, Tosetto, A, Oneto, R, Cavazzina, R, Rodeghiero, F, Bacigalupo, A, et al. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. Blood 120(6): 1327–33, 2012CrossRef Google Scholar PubMed

Hashmi, S, Oliva, JL, Liesveld, JL, Phillips, GL, Milner, L, Becker, MW. The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation. Leuk Res 37(9): 1052–6, 2013CrossRef Google Scholar PubMed

Mo, XD, Xu, LP, Liu, DH, Zhang, XH, Chen, H, Chen, YH, et al. The hematopoietic cell transplantation-specific comorbidity index (HCT-CI) is an outcome predictor for partially matched related donor transplantation. Am J Hematol 88(6): 497–502, 2013CrossRef Google Scholar PubMed

Bayraktar, UD, Shpall, EJ, Liu, P, Ciurea, SO, Rondon, G, de LM, et al. Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit. J Clin Oncol 31(33): 4207–14, 2013CrossRef Google Scholar PubMed

Chemnitz, JM, Chakupurakal, G, Basler, M, Holtick, U, Theurich, S, Shimabukuro-Vornhagen, A, et al. Pretransplant comorbidities maintain their impact on allogeneic stem cell transplantation outcome 5 years posttransplant: a retrospective study in a single German institution. ISRN Hematology: Article ID 853435, 2014Google Scholar

DeFor, TE, Majhail, NS, Weisdorf, DJ, Brunstein, CG, McAvoy, S, Arora, M, et al. A modified comorbidity index for hematopoietic cell transplantation. Bone Marrow Transplant 45(5): 933–8, 2010CrossRef Google Scholar PubMed

Birninger, N, Bornhäuser, M, Schaich, M, Ehninger, G, Schetelig, J. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation: investigation of potential limitations of the index. Biol Blood Marrow Transplant 17(12): 1822–32, 2011CrossRef Google Scholar PubMed

Terwey, TH, Hemmati, PG, Martus, P, Dietz, E, Vuong, LG, Massenkeil, G, et al. A modifed EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia. Haematologica 95(5): 810–8, 2010CrossRef Google Scholar

Xhaard, A, Porcher, R, Chien, JW, de Latour, RP, Robin, M, Ribaud, P, et al. Impact of comorbidity indexes on non-relapse mortality. Leukemia 22(11): 2062–9, 2008CrossRef Google Scholar PubMed

Guilfoyle, R, Demers, A, Bredeson, C, Richardson, E, Rubinger, M, Szwajcer, D, et al. Performance status, but not the hematopoietic cell transplantation comorbidity index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transplant 43(2): 133–9, 2009CrossRef Google Scholar PubMed

Castagna, L, Furst, S, Marchetti, N, El, CJ, Faucher, C, Mohty, M, et al. Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT. Bone Marrow Transplant 46(7): 1000–5, 2011CrossRef Google Scholar PubMed

Williams, M, Murray, J, Kulkarni, S, Bloor, A. HCT-CI correlates poorly with outcome following allogeneic stem cell transplant: impact of underlying diagnosis, patient selection and assessment of organ function. 38th Annual Meeting of the European Group for Blood and Marrow Transplantation. [Abstract] Bone Marrow Transplant 47(1): S205–S206, #646, 2012Google Scholar

Nakaya, A, Mori, T, Tanaka, M, Tomita, N, Nakaseko, C, Yano, S, et al. Does the hematopoietic cell transplantation specific comorbidity index predict transplantation outcomes? Biol Blood Marrow Transplant 20(10):1553–9, 2014CrossRef Google Scholar PubMed

Elsawy, M, Storer, BE, Pulsipher, MA, Maziarz, RT, Bhatia, S, Maris, MB, et al. Multi-centre validation of the prognostic value of the haematopoietic cell transplantation-specific comorbidity index among recipient of allogenic haematopoietic cell transplantation. Br J Haematol. 2015;170(4):574–83CrossRef Google Scholar PubMed

Imamura, K, McKinnon, M, Middleton, R, Black, N. Reliability of a comorbidity measure: the Index of Co-Existent Disease (ICED). J Clin Epidemiol 50(9): 1011–6, 1997CrossRef Google Scholar PubMed

Sorror, M. How I assess comorbidities prior to hematopoietic cell transplantation. Blood 121(15): 2854–63, 2013CrossRef Google Scholar

Pasquini, MC, Griffith, LM, Arnold, DL, Atkins, HL, Bowen, JD, Chen, JT, et al. Hematopoietic stem cell transplantation for multiple scerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies. Biol Blood Marrow Transplant 16(8): 1076–83, 2010CrossRef Google Scholar

Bentley, TS, Hanson, SG. U.S. organ and tissue transplant cost estimates and discussion. Milliman Research Report. Available at http://publications.milliman.com/research/health-rr/pdfs/2011-us-organ-tissue.pdf, 2011Google Scholar

Ortner, NJ. U.S. organ and tissue transplant cost estimates and discussion. Milliman Research Report, Available at: http://publications.milliman.com/research/health-rr/pdfs/US-Organ-Tissue-Transplant-2005-RR06-01–05.pdf, 2005Google Scholar

Comorbidity and Regimen Related Toxicity (RRT) Committee Report. Improving prognostic assessment for patients 60 years and older undergoing allogeneic HCT. BMT CTN State of the Science Symposium, Feb 24–25, 2014. Available at http://www.cvent.com/events/bmt-ctn-state-of-the-science-symposium/custom-17-d54c4d401ae642c4b2f549b39e52c539.aspx, 2014Google Scholar

Armand, P, Gibson, CJ, Cutler, C, Ho, VT, Koreth, J, Alyea, EP, et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 120(4): 905–13, 2012CrossRef Google Scholar PubMed

Deeg, HJ, Scott, BL, Fang, M, Shulman, HM, Gyurkocza, B, Myerson, D, et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 120(7): 1398–408, 201Google Scholar

Elsawy, M, Storer, BE, Sandmaier, B, Delaney, C, Appelbaum, F, Woolfrey, AE, et al. Role of comorbidities in prognostic evaluation of outcomes following allogeneic hematopoietic cell transplantation from HLA-mismatched and umbilical cord blood donor grafts. Blood 124:2583, 2014CrossRef Google Scholar

Sorror, ML, Logan, BR, Zhu, X, Rizzo, JD, Cooke, KR, McCarthy, PL, et al. Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index. Biol Blood Marrow Transplant 21(8):1479–87, 2015CrossRef Google Scholar PubMed

Book contents

Chapter 4 - Assessment of Comorbidities for Hematopoietic Cell Transplants: Achievements and Controversies

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive